BD (Becton, Dickinson and Company), a leading global medical technology company, announces the approval of the BD Saf-T-Intima™ Safety Integrated IV Catheter System for use in subcutaneous infusion ...

Subcutaneous Opdivo showed similar efficacy and safety to intravenous Opdivo in advanced ccRCC, with a slightly higher overall response rate. The CheckMate-67T trial confirmed pharmacokinetic and ...

AMSTERDAM — Subcutaneous tocilizumab demonstrated comparable safety and efficacy to IV tocilizumab in patients with systemic juvenile idiopathic arthritis, according to data presented at the EULAR ...

IV hydration spas are popping up across the United States, offering pricey vitamin infusions that promise energy, detox or immune support, but experts warn the science doesn't back up those claims.

Subcutaneous Sarclisa, administered via OBDS, showed non-inferior efficacy to IV Sarclisa in relapsed/refractory multiple myeloma patients. The IRAKLIA study enrolled 532 patients globally, ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window MILAN -- An ...

Johnson & Johnson’s attempt to switch physicians from intravenous to subcutaneous Darzalex is almost complete. Having won FDA approval for Darzalex Faspro in May 2020, J&J has converted 85% of its U.S ...

Nearly 90% of patients with relapsing-remitting MS in a multicenter study in Germany preferred subcutaneous administration of Tysabri rather than IV, citing shorter duration of delivery and ...

Roche Holdings AG's RHHBY Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with ...

Roche’s Lunsumio may be the first CD20xCD3 T-cell engager approved by the FDA, but intravenous administration puts the drug at a disadvantage to AbbVie and Genmab’s subcutaneously injected Epkinly.

RAHWAY, N.J., March 27, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first data presentation from the pivotal 3475A-D77 Phase 3 ...